China National Accord Medicines Corporation Ltd.
First Quarterly Report 2013
April 2013
1
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord Medicines Corporation Ltd.
(hereinafter referred to as the Company) and its directors, supervisors and senior executives should guarantee the
reality, accuracy and completion of the quarterly report, there are no any fictitious statements, misleading
statements or important omissions carried in this report, and shall take legal responsibilities, individual and/or
joint.
Yan Zhigang, person in charge of the Company, Wei Pingxiao, person in charger of accounting works and Chi
Guoguang, person in charger of accounting organ (accounting officer) hereby confirm that the Financial Report of
this Quarterly Report is authentic, accurate and complete.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
2
Section II. Main financial data and changes of shareholders
I. Main financial data
Whether has retroactive adjustment or re-statement on financial data of previous’ period in this report or not
□Yes √ No
Changes of this period over
Jan. – March 2013 Jan. – March 2012
same period of last year (%)
Operating income (RMB) 4,868,822,373.35 4,274,691,013.50 13.9%
Net profit attributable to shareholders of
143,654,533.90 121,822,129.24 17.92%
the listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting 141,497,888.97 121,014,539.71 16.93%
non-recurring gains and losses(RMB)
Net cash flow arising from operating
109,790,134.68 -271,437,536.92 140.45%
activities(RMB)
Basic earnings per share (RMB/Share) 0.499 0.423 17.97%
Diluted earnings per share (RMB/Share) 0.499 0.423 17.97%
Weighted average ROE (%) 7.77% 8.63% -0.86%
Changes of this period-end
2013-3-31 2012-12-31 over same period-end of last
year (%)
Total assets (RMB) 9,675,831,669.40 9,295,839,939.64 4.09%
Net assets attributable to shareholder of
1,919,758,562.86 1,775,943,028.96 8.1%
listed company (RMB)
Whether shares capital changes and owners equity been affected due to new shares issued, additional offering, allotment of shares,
equity incentive exercise and buy-back from this period-end to date of report disclosed or not
□Yes √ No
Items of non-recurring gains and losses
√ Applicable □ Not applicable
Unit: RMB
Amount from year-begin to
Item Note
period-end
Gains/losses from the disposal of non-current asset (including the
-227.82
write-off that accrued for impairment of assets)
Tax refund or exemption out of authorization, with absence of
official approval document or accidentally
Governmental subsidy reckoned into current gains/losses (not 2,095,437.72 Mainly because the Company
3
including the subsidy enjoyed in quota or ration according to received financial discount
national standards, which are closely relevant to enterprise’s 150,000 yuan, the subsidiary of
business) the Company received vary
subsidy of stock medicine
subsidies as 1.24 million yuan,
received high-tech R&D project
funds 200,000 yuan, received
Zhongshan Health
Pharmaceutical Industry
Development Special Fund and
leading enterprise entrance
one-time grant 100,000 yuan.
Fund occupation expenses received from non-financial
enterprises that reckon into current gains/losses
Income occurred when investment cost paid by enterprise for
obtaining subsidiaries, associates and joint ventures are lower
than its share in fair value of net realizable assets of invested
units
Gains and losses from exchange of non-monetary assets
Gains and losses from entrusted investment or management assets
Various asset impairment reserve provided for force majeure,
such as natural disaster;
Gains/losses from debt reorganization
Reorganization expenses, such as expenditure for allocation of
employees and integration fee
Gains and losses from excess of transaction which are conducted
on a non-fair-valued basis over its fair value
Current net gains and losses of subsidiaries occurred from
combination under the same control commencing from
period-begin to combination date
Gains and losses from contingent events which has no relation
with normal business of the Company
Gains and losses from change of fair values of
held-for-transaction financial assets and financial liabilities except
for the effective hedge business related to normal business of the
Company, and investment income from disposal of transactional
financial assets and liabilities and financial assets available for
sale
Reversal of impairment reserve for account receivable with
542,875.59
separate impairment testing
Gains/ losses from external entrustment loans
Gains and losses arising from change of fair value of investment
properties whose follow-up measurement are at fair value
Affect upon current gains/losses arising from the one-off
adjustment in subject to requirement of laws and rules in relation
to taxation and accounting
Income from entrusted custody operation
Other non-operating income and expenditure except for the
135,928.77
aforementioned items
Other item that satisfied the definition of non-recurring gains and
losses
4
Impact on income tax 588,295.57
Impact on minority shareholders’ equity (post-tax) 29,073.76
Total 2,156,644.93 --
Note: 1.The non-recurring profit and loss items listed according to the pretax amount.
2. Please fill it out to a negative number if there is a negative number in the non-recurring profit and loss items.
II. Total number of shareholders at the end of this report period and top ten shareholders
Unit: Share
Total number of shareholders
12,500
at the end of report period
Top ten shareholders
Amount of Number of share pledged/frozen
Shareholder’s Nature of Proportion of Amount of shares
restricted shares
name shareholder shares held (%) held State of share Amount
held
Sinopharm Group State-owned legal
38.33% 110,459,748 0
Co., Ltd. person
ABC—Invesco
Greatwall
Domestic non
Domestic
state-owned legal 3.16% 9,109,464
Demand Growth
person
II stock securities
investment fund
HTHK/CMG
FSGUFP-CMG
Foreign legal
FIRST STATE 2.44% 7,032,720
person
CHINA
GROWTH FD
VALUE
Foreign legal
PARTNERS 2.36% 6,812,622
person
CLASSIC FUND
ICBC—Harvest
Theme New Domestic non
Power stock state-owned legal 2.35% 6,785,060
securities person
investment fund
CCB—China
International Domestic non
Alpha stock state-owned legal 1.45% 4,180,898
securities person
investment fund
5
BOC—Harvest
Research Domestic non
Selected stock state-owned legal 1.43% 4,128,444
securities person
investment fund
ICBC—Harvest
Domestic non
Strategic Growth
state-owned legal 1.43% 4,126,862
hybrid securities
person
investment fund
ICBC－
Domestic non
GUANGFA
state-owned legal 1.39% 4,000,000
JUFENG STOCK
person
FUND
National Social Domestic non
Security Fund state-owned legal 1.09% 3,135,180
102 combination person
Top ten shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
CCB—China Advantage Growth RMB ordinary
9,109,464 9,109,464
stock securities investment fund shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,032,720 listed foreign 7,032,720
STATE CHINA GROWTH FD
shares
Domestically
VALUE PARTNERS CLASSIC
6,812,622 listed foreign 6,812,622
FUND
shares
ICBC—Harvest Theme New Power RMB ordinary
6,785,060 6,785,060
stock securities investment fund shares
CCB—China International Alpha RMB ordinary
4,180,898 4,180,898
stock securities investment fund shares
BOC—Harvest Research Selected RMB ordinary
4,128,444 4,128,444
stock securities investment fund shares
ICBC—Harvest Strategic Growth RMB ordinary
4,126,862 4,126,862
hybrid securities investment fund shares
ICBC－GUANGFA JUFENG RMB ordinary
4,000,000 4,000,000
STOCK FUND shares
National Social Security Fund 102 RMB ordinary
3,135,180 3,135,180
combination shares
6
ICBC—Harvest Theme New Power stock securities investment fund and ICBC—Harvest
Strategic Growth hybrid securities investment fund has the same fund manager of Harvest
Fund Management Co., LTD; As an investment manager, VALUE PARTNERS is in charging
Note of related relationship among
of 19 funds and entrusted accounts in total. VALUE PARTNERS CLASSIC FUND, one of
the above shareholders and
the top ten shareholders, is one of the VALUE PARTNERS; it is unknown that there exists no
concerted actors
associated relationship or belongs to the consistent actionist among the other tradable
shareholders regulated by the Management Measure of Information Disclosure on Change of
Shareholding for Listed Companies.
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
1. Other current assets: decreased 3.07 million yuan over that of balance at period-begin with growth rate of -37.95%, mainly because
the offset against VAT payable decreased;
2. Wages payable: decreased 48.68 million yuan over that of balance at period-begin with growth rate of -31.21%, mainly because
the remuneration, accrual last year, has distributed in this period;
3. Interest payable: increased 5.06 million yuan over that of balance at period-begin with growth rate of 38.79%, mainly because
short-term financing bonds interest was newly accrual in this period;
4. Long-term account payable: decreased 30,000 yuan over that of balance at period-begin with growth rate of -100.00%, mainly
because completed the payment of staff’s seniority compensation of subsidiaries in this period;
5. Assets impairment loss: a y-o-y growth of 9.5 million yuan with rate of 4320.11% up, mainly because on one hand, less accrual
provision for obsolete stocks at same period of last year due to the strengthen in inventory management and quickening inventory
turnover; on the other hand, the accrual provision for obsolete stocks increased in this period due to the influence from antibiotic
restriction policy in pharmaceutical industry;
6. Non-operation expenditure: a y-o-y decrease of 0.38 million yuan with rate of -87.79% up, mainly because y-o-y down in external
donation and loss from disposal of non-current assts in this period;
7. Minority interest: a y-o-y growth of 2.43 million yuan with rate of 247.71% up, mainly because on one hand, a y-o-y growth of
profit from subsidiary, the minority interest increased; on the other hand, influence from the minority equity acquisition of
subsidiary;
8. Tax refunds received: a y-o-y growth of 70,000 yuan with rate of 42.56% up, mainly because export tax refunds from subsidiary
increased y-o-y;
9. Net cash flow from operation activity: a y-o-y growth of 381.23 million yuan, mainly benefit from the y-o-y growth of sales, cash
received from commodity sales and labor service providing increased y-o-y;
10. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: a y-o-y decrease of 0.15 million
yuan with rate of -71.31% up, mainly because part of the vehicle has disposed at same period of last year while no such business
occurred in this period;
11. Cash paid for purchasing fixed assets, intangible assets and other long-term assets: a y-o-y decreases of 28.38 million yuan with
rate of -62.54% up, mainly because final payment for part of the construction completion at same period of last year;
12. Net cash paid for subsidiary and other operation units obtained: a y-o-y decreases of 5.09 million yuan with rate of -100% up,
7
mainly because purchase Sinopharm Zhaoqing and Sinopharm Wuzhou at same period of last year while no such business occurred
in this period;
13. Net cash flow from investment activity: a y-o-y growth of 33.32 million yuan with rate of 66.30% up, mainly because the cash
paid for purchasing fixed assets, intangible assets and other long-term assets and net cash paid for subsidiary and other operation
units obtained decreased y-o-y;
14. Cash from loans: a y-o-y decreases of 191.70 million yuan with rate of -53.79% up, mainly because offered short-term financing
bonds in 2nd half year of last year and the borrowing scale from the bank down y-o-y in this period;
15. Cash received with other financing activity concerned: a y-o-y decreases of 345.26 million yuan with rate of -100.00% up, mainly
because no entrust loans borrow-in in this period and at same period of last year, the account collected and paid of supply chain
financing for the bank was listed base on the amount incurred while listed base on net amount in this year;
16. Cash paid with other financing activity concerned: a y-o-y decreases of 293.28 million yuan with rate of -92.42% up, mainly
because no entrust loans paid in this period and at same period of last year, the account collected and paid of supply chain financing
for the bank was listed base on the amount incurred while listed base on net amount in this year;
17. Net cash flow from financing activity: a y-o-y decreases of 214.54 million yuan with rate of -158.49% up, mainly because offered
short-term financing bonds in 2nd half year of last year and the borrowing scale from the bank down y-o-y in this period;
18. Influence on cash and cash equivalent from exchange rate movement: a y-o-y increases of 2,900 yuan with rate of 99.99% up,
mainly because less foreign currency held.
II. Analysis and explanation of significant events and their influence and solutions
Nil
III. Predict of the business performance from January to June 2013
Warnings and reasons of the predict that the cumulative net profit from the begin of the year to the end of next report period may be
loss or have great changes comparing with the same period of last year
□Applicable √Not applicable
IV. Registration form for receiving research, communication and interview in the report
period
Contents discussed and
Date Place Method Type of investors Investor
materials supplied
Visited the company and
Huatai Financial
Accord Pharm. knew the development of
2013-01-09 Spot investigation Institution Holdings, Fortune
Bldg. the company. No material
SG Fund
provided.
E Fund, Guosen Visited the company and
Accord Pharm. Securities, China knew the development of
2013-01-10 Spot investigation Institution
Bldg. Merchants Fund, the company. No material
Orient Securities provided.
Industrial
Securities, Visited the company and
Accord Pharm. China AMC, CCB knew the development of
2013-03-29 Spot investigation Institution
Bldg. Principal Asset, the company. No material
Chinalion provided.
Securities
8
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
Unit: RMB
Items Balance at period-end Balance at period-begin
Current assets:
Monetary funds 953,410,093.68 953,992,070.61
Settlement provisions
Capital lent
Transaction finance asset
Notes receivable 680,988,657.17 650,860,240.37
Accounts receivable 4,836,922,169.95 4,393,325,300.66
Accounts paid in advance 94,021,326.75 89,512,381.34
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable
Dividend receivable
Other receivables 34,049,047.45 32,985,425.60
Purchase restituted finance asset
Inventories 1,636,075,613.82 1,734,679,063.78
Non-current asset due within one
year
Other current assets 5,014,332.64 8,080,607.66
Total current assets 8,240,481,241.46 7,863,435,090.02
Non-current assets:
Granted loans and advances
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
9
Long-term equity investment 130,280,735.30 121,019,845.50
Investment property 82,702,191.19 88,315,429.63
Fixed assets 681,739,701.44 690,487,633.12
Construction in progress 112,202,581.42 103,955,350.80
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 154,266,247.96 155,155,071.20
Expense on Research and
5,126,782.49 5,002,441.27
Development
Goodwill 85,228,833.15 85,228,833.15
Long-term expenses to be
18,884,334.00 19,742,990.45
apportioned
Deferred income tax asset 52,127,861.80 49,509,529.97
Other non-current asset 112,791,159.19 113,987,724.53
Total non-current asset 1,435,350,427.94 1,432,404,849.62
Total assets 9,675,831,669.40 9,295,839,939.64
Current liabilities:
Short-term loans 1,827,285,217.34 1,687,810,294.37
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Transaction financial liabilities
Notes payable 1,311,910,404.19 1,105,275,538.24
Accounts payable 3,136,115,910.19 3,197,354,275.46
Accounts received in advance 27,224,624.59 35,002,695.02
Selling financial asset of
repurchase
Commission charge and
commission payable
Wage payable 107,315,804.90 155,994,408.20
Taxes payable 66,450,815.20 51,390,674.43
Interest payable 18,091,827.73 13,035,821.07
Dividend payable
10
Other accounts payable 402,488,659.33 413,831,307.40
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Non-current liabilities due within 1
59,000,000.00 71,127,275.00
year
Other current liabilities 399,427,039.55 399,014,838.05
Total current liabilities 7,355,310,303.02 7,129,837,127.24
Non-current liabilities:
Long-term loans 89,332,837.71 82,205,562.71
Bonds payable
Long-term account payable 32,259.60
Special accounts payable 4,326,000.00 4,487,000.00
Projected liabilities
Deferred income tax liabilities 26,209,837.73 26,619,273.68
Other non-current liabilities 214,376,320.99 213,607,504.21
Total non-current liabilities 334,244,996.43 326,951,600.20
Total liabilities 7,689,555,299.45 7,456,788,727.44
Owner’s equity (or shareholders’
equity):
Paid-in capital (or share capital) 288,149,400.00 288,149,400.00
Capital public reserve 5,711,338.57 5,550,338.57
Less: Inventory shares
Reasonable reserve
Surplus public reserve 99,360,384.15 99,360,384.15
Provision of general risk
Retained profit 1,526,537,440.14 1,382,882,906.24
Balance difference of foreign
currency translation
Total owner’s equity attributable to
1,919,758,562.86 1,775,943,028.96
parent company
Minority interests 66,517,807.09 63,108,183.24
Total owner’s equity (or shareholders’
1,986,276,369.95 1,839,051,212.20
equity)
Total liabilities and owner’s equity(or
9,675,831,669.40 9,295,839,939.64
shareholders’ equity)
11
Legal representative: Yan Zhigang
Person in charger of accounting works: Wei Pingxiao
Person in charger of accounting organ: Chi Guoguang
2. Balance sheet of parent company
Prepared by China National Accord Medicines Corporation Ltd.
Unit: RMB
Items Balance at period-end Balance at period-begin
Current assets:
Monetary funds 160,010,841.35 160,633,355.13
Transaction finance asset 0.00 0.00
Notes receivable 8,410,528.75 376,521.35
Accounts receivable 372,409,256.88 364,688,936.84
Accounts paid in advance 2,494,343.12 2,944,282.55
Interest receivable 0.00 0.00
Dividend receivable 0.00 0.00
Other receivables 858,743,244.71 971,859,991.32
Inventories 137,965,918.04 130,552,057.09
Non-current asset due within one
0.00 0.00
year
Other current assets 2,144,893.01 262,096.80
Total current assets 1,542,179,025.86 1,631,317,241.08
Non-current assets:
Finance asset available for sales 0.00 0.00
Held-to-maturity securities 0.00 0.00
Long-term account receivable 0.00 0.00
Long-term equity investment 1,478,310,229.68 1,469,049,339.88
Investment property 6,321,983.43 7,392,314.49
Fixed assets 26,979,421.76 27,728,901.07
Construction in progress 727,907.49 545,247.24
Engineering material 0.00 0.00
Disposal of fixed asset 0.00 0.00
Productive biological asset 0.00 0.00
Oil and gas asset 0.00 0.00
Intangible assets 37,601,729.65 37,903,901.08
Expense on Research and
0.00 0.00
Development
Goodwill 0.00 0.00
12
Long-term expenses to be
7,616,829.39 7,893,858.54
apportioned
Deferred income tax asset 2,946,203.12 2,929,885.67
Other non-current asset 8,350,000.00 8,350,000.00
Total non-current asset 1,568,854,304.52 1,561,793,447.97
Total assets 3,111,033,330.38 3,193,110,689.05
Current liabilities:
Short-term loans 388,000,000.00 452,004,475.38
Transaction financial liabilities 0.00 0.00
Notes payable 151,087,958.14 176,012,796.90
Accounts payable 316,748,895.50 282,426,136.11
Accounts received in advance 15,323.51 477,717.18
Wage payable 24,645,045.86 28,849,468.43
Taxes payable 697,317.82 715,642.50
Interest payable 11,292,505.15 7,091,864.58
Dividend payable 0.00 0.00
Other accounts payable 536,479,892.30 575,130,189.97
Non-current liabilities due within 1
0.00 0.00
year
Other current liabilities 399,427,039.55 399,014,838.05
Total current liabilities 1,828,393,977.83 1,921,723,129.10
Non-current liabilities:
Long-term loans 0.00 0.00
Bonds payable 0.00 0.00
Long-term account payable 0.00 0.00
Special accounts payable 839,000.00 1,000,000.00
Projected liabilities 0.00 0.00
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities 0.00 0.00
Total non-current liabilities 4,612,319.00 4,773,319.00
Total liabilities 1,833,006,296.83 1,926,496,448.10
Owner’s equity (or shareholders’
equity):
Paid-in capital (or share capital) 288,149,400.00 288,149,400.00
Capital public reserve 14,509,726.93 14,348,726.93
13
Less: Inventory shares 0.00 0.00
Reasonable reserve 0.00 0.00
Surplus public reserve 99,360,384.15 99,360,384.15
Provision of general risk 0.00 0.00
Retained profit 876,007,522.47 864,755,729.87
Balance difference of foreign
0.00
currency translation
Total owner’s equity(or shareholders’
1,278,027,033.55 1,266,614,240.95
equity)
Total liabilities and owner’s equity(or
3,111,033,330.38 3,193,110,689.05
shareholders’ equity)
Legal representative: Yan Zhigang
Person in charger of accounting works: Wei Pingxiao
Person in charger of accounting organ: Chi Guoguang
3. Consolidated Profit Statement
Prepared by China National Accord Medicines Corporation Ltd.
Unit: RMB
Items Amount at this period Amount at last period
I. Total operating income 4,868,822,373.35 4,274,691,013.50
Including: Operating income 4,868,822,373.35 4,274,691,013.50
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 4,699,206,221.19 4,128,175,649.52
Including: Operating cost 4,432,050,849.23 3,880,365,134.83
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 11,692,662.54 10,249,357.93
Sales expenses 127,880,683.95 115,542,181.90
Administration expenses 84,756,689.56 76,371,797.88
14
Financial expenses 33,105,615.62 45,427,279.11
Losses of devaluation of asset 9,719,720.29 219,897.87
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed
9,260,889.80 7,133,029.51
with “-”)
Including: Investment income on
9,260,889.80 7,133,029.51
affiliated company and joint venture
Exchange income (Loss is listed
with “-”)
III. Operating profit (Loss is listed
178,877,041.96 153,648,393.49
with “-”)
Add: Non-operating income 2,283,793.08 1,880,398.82
Less: Non-operating expense 52,654.41 431,395.93
Including: Disposal loss of
18,690.05 81,021.97
non-current asset
IV. Total Profit (Loss is listed with
181,108,180.63 155,097,396.38
“-”)
Less: Income tax 34,044,022.88 32,294,666.00
V. Net profit (Net loss is listed with “-”) 147,064,157.75 122,802,730.38
Including: Net profit achieved by the
merged party before the merger
Net profit attributable to owner’s
143,654,533.90 121,822,129.24
equity of parent company
Minority shareholders’ gains and
3,409,623.85 980,601.14
losses
VI. Earnings per share -- --
i. Basic earnings per share 0.499 0.423
ii. Diluted earnings per share 0.499 0.423
VII. Other consolidated income
VIII. Total consolidated income 147,064,157.75 122,802,730.38
Total consolidated income attributable
143,654,533.90 121,822,129.24
to owners of parent company
Total consolidated income
3,409,623.85 980,601.14
attributable to minority shareholders
Legal representative: Yan Zhigang
Person in charger of accounting works: Wei Pingxiao
Person in charger of accounting organ: Chi Guoguang
Notes: financial expenses involved financial business should be separately listed the items of exchange gains
4. Profit statement of parent company
15
Prepared by China National Accord Medicines Corporation Ltd.
Unit: RMB
Items Amount at this period Amount at last period
I. Operating income 556,966,727.71 525,423,059.94
Less: Operating income 533,556,373.38 498,089,934.80
Operating tax and extras 967,482.15 1,330,854.18
Sales expenses 9,712,242.94 9,591,216.16
Administration expenses 8,476,872.55 9,925,545.34
Financial expenses 2,364,622.69 6,891,875.19
Losses of devaluation of asset 73,319.88 -402,728.39
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed
9,260,889.80 7,569,709.80
with “-”)
Including: Investment income on
9,260,889.80 7,133,029.51
affiliated company and joint venture
II. Operating profit (Loss is listed
11,076,703.92 7,566,072.46
with “-”)
Add: Non-operating income 158,771.23 246,516.01
Less: Non-operating expense 269,125.07
Including: Disposal loss of
69,125.07
non-current asset
III. Total Profit (Loss is listed with
11,235,475.15 7,543,463.40
“-”)
Less: Income tax -16,317.45
IV. Net profit (Net loss is listed with
11,251,792.60 7,543,463.40
“-”)
V. Earnings per share -- --
i. Basic earnings per share 0 0
ii. Diluted earnings per share 0 0
VI. Other consolidated income 0.00 0.00
VII. Total consolidated income 11,251,792.60 7,543,463.40
Legal representative: Yan Zhigang
Person in charger of accounting works: Wei Pingxiao
Person in charger of accounting organ: Chi Guoguang
5. Consolidated cash flow statement
Prepared by China National Accord Medicines Corporation Ltd.
Unit: RMB
16
Items Amount at this period Amount at last period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 4,735,572,728.08 3,779,498,907.42
services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Insured savings and net increase of
investment
Net increase of disposal of
transaction financial asset
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 232,694.10 163,222.89
Other cash received concerning
19,078,366.15 17,797,483.61
operating activities
Subtotal of cash inflow arising
4,754,883,788.33 3,797,459,613.92
from operating activities
Cash paid for purchasing
commodities and receiving labor 4,295,639,508.28 3,725,221,147.10
service
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
17
slip
Cash paid to/for staff and workers 162,986,417.08 139,233,755.22
Taxes paid 114,701,822.78 103,980,345.49
Other cash paid concerning
71,765,905.51 100,461,903.03
operating activities
Subtotal of cash outflow arising
4,645,093,653.65 4,068,897,150.84
from operating activities
Net cash flows arising from
109,790,134.68 -271,437,536.92
operating activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
income
Net cash received from disposal of
fixed, intangible and other long-term 59,661.00 207,915.00
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
Subtotal of cash inflow from
59,661.00 207,915.00
investing activities
Cash paid for purchasing fixed,
16,994,763.75 45,372,897.36
intangible and other long-term assets
Cash paid for investment
Net increase of mortgaged loans
Net cash received from
5,085,907.61
subsidiaries and other units
Other cash paid concerning
investing activities
Subtotal of cash outflow from
16,994,763.75 50,458,804.97
investing activities
Net cash flows arising from
-16,935,102.75 -50,250,889.97
investing activities
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Including: Cash received from
absorbing minority shareholders’
18
investment by subsidiaries
Cash received from loans 164,699,901.11 356,403,865.78
Cash received from issuing bonds
Other cash received concerning
345,255,690.18
financing activities
Subtotal of cash inflow from
164,699,901.11 701,659,555.96
financing activities
Cash paid for settling debts 191,180,079.92 211,686,102.18
Cash paid for dividend and profit
28,634,662.45 37,264,660.38
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by
subsidiaries
Other cash paid concerning
24,064,510.17 317,345,129.32
financing activities
Subtotal of cash outflow from
243,879,252.54 566,295,891.88
financing activities
Net cash flows arising from
-79,179,351.43 135,363,664.08
financing activities
IV. Influence on cash due to fluctuation
-0.28 -2,940.42
in exchange rate
V. Net increase of cash and cash
13,675,680.22 -186,327,703.23
equivalents
Add: Balance of cash and cash
920,748,043.53 907,884,162.14
equivalents at the period -begin
VI. Balance of cash and cash
934,423,723.75 721,556,458.91
equivalents at the period -end
Legal representative: Yan Zhigang
Person in charger of accounting works: Wei Pingxiao
Person in charger of accounting organ: Chi Guoguang
6. Cash flow statement of parent company
Prepared by China National Accord Medicines Corporation Ltd.
Unit: RMB
Items Amount at this period Amount at last period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 601,851,075.97 484,645,217.07
services
Write-back of tax received
Other cash received concerning
2,756,834.53 3,557,267.61
operating activities
19
Subtotal of cash inflow arising
604,607,910.50 488,202,484.68
from operating activities
Cash paid for purchasing
commodities and receiving labor 595,766,405.98 479,168,053.99
service
Cash paid to/for staff and workers 14,068,634.25 15,761,713.23
Taxes paid 3,254,198.36 5,045,537.47
Other cash paid concerning
8,044,724.40 27,322,022.51
operating activities
Subtotal of cash outflow arising
621,133,962.99 527,297,327.20
from operating activities
Net cash flows arising from
-16,526,052.49 -39,094,842.52
operating activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
11,455,495.83 9,752,052.28
income
Net cash received from disposal of
fixed, intangible and other long-term 207,900.00
assets
Net cash received from disposal of
5,424,600.00
subsidiaries and other units
Other cash received concerning
212,500,000.00 125,500,000.00
investing activities
Subtotal of cash inflow from
223,955,495.83 140,884,552.28
investing activities
Cash paid for purchasing fixed,
886,809.08 942,800.00
intangible and other long-term assets
Cash paid for investment
Net cash received from
3,542,000.00
subsidiaries and other units
Other cash paid concerning
97,700,000.00 48,880,000.00
investing activities
Subtotal of cash outflow from
98,586,809.08 53,364,800.00
investing activities
Net cash flows arising from investing
125,368,686.75 87,519,752.28
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
20
investment
Cash received from loans 70,000,000.00 70,000,000.00
Cash received from issuing bonds
Other cash received concerning
86,167,361.60 228,648,356.64
financing activities
Subtotal of cash outflow from financing
156,167,361.60 298,648,356.64
activities
Cash paid for settling debts 134,000,000.00 90,062,726.66
Cash paid for dividend and profit
11,132,509.64 16,534,200.84
distributing or interest paying
Other cash paid concerning
120,500,000.00 282,001,352.06
financing activities
Subtotal of cash outflow from
265,632,509.64 388,598,279.56
financing activities
Net cash flows arising from
-109,465,148.04 -89,949,922.92
financing activities
IV. Influence on cash due to fluctuation
in exchange rate
V. Net increase of cash and cash
-622,513.78 -41,525,013.16
equivalents
Add: Balance of cash and cash
160,633,355.13 164,840,499.86
equivalents at the period -begin
VI. Balance of cash and cash
160,010,841.35 123,315,486.70
equivalents at the period -end
Legal representative: Yan Zhigang
Person in charger of accounting works: Wei Pingxiao
Person in charger of accounting organ: Chi Guoguang
II. Audit report
Whether the first quarterly report had been audited or not
□ Yes √ No
21
